Identification of highly cross-reactive mimotopes for a public T cell response in murine melanoma

Beth E. Grace^{1,2}, Coralie M. Backlund^{1,2}, Duncan M. Morgan^{2,3}, Byong H. Kang^{1,2}, Nishant K. Singh^{1,2,4}, Brooke D. Huisman^{1,2}, C. Garrett Rappazzo^{1,2,†}, Kelly D. Moynihan^{1,2}, Laura Maiorino^{1,2}, Connor S. Dobson^{1,2}, Taeyoon Kyung^{1,2}, Khloe S. Gordon^{1,2}, Patrick V. Holec^{1,2}, Overbeck C. Takou Mbah⁴, Daniel Garafola², Shengwei Wu², J. Christopher Love^{2,3,4}, K. Dane Wittrup^{1,2,3}, Darrell J. Irvine^{1,2,4}, Michael E. Birnbaum^{1,2,4,*}

¹ Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, United States

² Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, United States

³ Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, United States

⁴ Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, United States

† Present address: Adimab LLC, Lebanon, NH, United States

* Correspondence:

Michael E. Birnbaum

mbirnb@mit.edu

Keywords: mimotope, endogenous retrovirus, T cell receptor, antigen, melanoma

Abstract

While immune checkpoint blockade results in durable responses for some patients, many others have not experienced such benefits. These treatments rely upon reinvigorating specific T cell-antigen interactions. However, it is often unknown what antigens are being recognized by T cells or how to potently induce antigen-specific responses in a broadly applicable manner. Here, we characterized the CD8⁺ T cell response to a murine model of melanoma following combination immunotherapy to determine the basis of tumor recognition. Sequencing of tumor-infiltrating T cells revealed a repertoire of highly homologous TCR sequences that were particularly expanded in treated mice and which recognized an antigen from an endogenous retrovirus. While vaccination against this peptide failed to raise a protective T cell response *in vivo*, engineered antigen mimotopes induced a significant expansion of CD8⁺ T cells cross-reactive to the original antigen. Vaccination with mimotopes resulted in killing of antigen-loaded cells *in vivo* yet showed modest survival benefit in a prophylactic vaccine paradigm. Together, this work demonstrates the identification of a dominant tumor-associated antigen and generation of mimotopes which can induce robust functional T cell responses that are cross-reactive to the endogenous antigen across multiple individuals.

35 Introduction

36 Immune checkpoint blockade (ICB) therapies such as anti-PD-1 and anti-CTLA-4 antibodies have
 37 revolutionized the field of immunotherapy. These therapies work by reinvigorating pre-existing anti-
 38 tumor T cell responses in cancer patients (1). However, it is often difficult to identify the antigen or
 39 set of antigens that is being targeted in ICB therapies. While patient-specific neoantigens represent
 40 a significant proportion of anti-tumor immune responses (2), there are also shared antigens that
 41 can each contribute to strong anti-tumor immunity, including common oncogenic mutations, tissue
 42 lineage antigens, and viral antigens (3,4). Thus, identification and characterization of antigens that
 43 correlate with successful ICB therapies is essential. Recognition of these antigens may represent a
 44 prognostic marker for the potential success of ICB therapies, or the antigens may themselves be
 45 targeted in combination therapies with the aim of further expanding the pool of patients that
 46 benefit from the extended survival these therapies can offer (5).

47 The combination of antigen-targeted vaccines and ICB is expected to be synergistic, since vaccines
 48 can expand tumor-specific T cells and ICB can allow the T cell response to proceed uninhibited by
 49 checkpoint mediated suppression (6). Many classes of putative tumor antigens tend to activate
 50 their cognate T cells less potently than pathogen-derived antigens, at least in part due to deletion of
 51 the most potent T cell clones against self-antigens via thymic selection (7). Peptide mimics of an
 52 antigen, referred to as mimotopes or altered peptide ligands, may be able to induce a stronger T
 53 cell response to the native antigen by more potently engaging with a given T cell receptor (TCR)
 54 than the native antigen (8,9). Given the extensive cross reactivity of T cells (10–12), mimotopes can
 55 be used to expand a population of T cells that overlap with the population that recognize the native
 56 antigen (13,14). In this way, mimotopes can be utilized as a vaccine, resulting in the expansion of a
 57 population of reactive T cells that can also recognize the native antigen when it is presented by
 58 tumor cells. Mimotopes have also previously been used to mobilize low-avidity self-specific T cells
 59 (8,15).

60 Here, we investigate the tumor-infiltrating T cell response following combination therapy in the
 61 well-studied, poorly immunogenic B16F10 murine model of melanoma. We identify a set of
 62 strikingly similar T cell clones shared both within individual immune repertoires and between
 63 animals and determine the antigen recognized by these clones. We then use a yeast display pMHC
 64 library approach to identify and characterize two antigen mimotopes that potently activate T cells.
 65 This work supports the utility of mimotopes for the improvement and expansion of T cell responses
 66 against tumor-associated antigens.

67 Results

68 *The immune response following combination immunotherapy is oligoclonal and includes a set of* 69 *highly conserved T cell clones*

70 We first set out to characterize the T cell response in C57BL/6 mice following treatment of B16F10
 71 melanoma with a combination therapy that has been previously shown to induce a robust
 72 protective immune response. The therapy, known as AIP, combines the Trp1-targeting antibody
 73 TA99 (A), extended half-life IL-2 (I), and an anti-PD-1 antibody (P), and results in cures in about half
 74 of mice with B16F10 melanoma (16). While a four-component version of the therapy, known as
 75 AIPV, also includes an amphiphile peptide vaccine targeting Trp2, we focused upon AIP in this study

as it is more representative of current combination ICB therapies and does not direct the response to a particular antigen. Further, previous studies demonstrated that in the absence of a peptide vaccine component, AIP is effective yet primarily targets an antigen that is distinct from Trp2 (16). We single-cell sorted and sequenced the T cell receptors of activated tumor-infiltrating lymphocytes (TILs) in either AIP-treated or untreated mice. The AIP therapy was administered on days 8 and 15 following tumor inoculation, and IFN- γ -secreting CD8⁺ TILs were sorted on day 21 and sequenced (**Figure 1A**).

Analysis of the TCR repertoire from recovered TILs demonstrated an oligoclonal immune response, with 40-75% of the IFN- γ ⁺ CD8⁺ T cell response consisting of three to four dominant clones. Interestingly, both AIP-treated and untreated mice demonstrated similarly oligoclonal responses (**Figure 1B**). The presence of multiple large clones may indicate that the untreated mice are mounting an immune response to the tumor, albeit not one effective enough to reduce tumor burden without additional intervention. In AIP-treated mice, CD8⁺ T cell infiltration in tumors was tenfold higher than in untreated mice (**Supplementary Figure 1A**), suggestive of highly expanded T cell clones in AIP-treated mice, although the fraction of CD8⁺ T cells that was activated was similar in treated and untreated mice (**Supplementary Figure 1B**).

Upon analysis of CDR3 sequences of the T cells, we identified two highly similar CDR3 α sequences which were highly represented in our data (**Table 1**); clones containing these sequences are colored orange (**Figure 1B**). Each of these sequences relied upon TRAJ7 in forming the CDR3 sequence, with a small degree of variation due to V-J junctional diversity. These CDR3 α sequences were present in several of the dominant clones, particularly in treated mice, while also appearing occasionally in the untreated pool. In addition to the strikingly similar CDR3 regions, the expanded TCRs showed a restricted TRAV repertoire, with the variable regions having similarities in their CDR1 and CDR2 sequences (**Supplementary Figure 1C**).

The beta chains paired with these alpha chains varied overall, but there were some similarities among the CDR3 β sequences, such as a PPG motif present in 7 out of 14 sequences and frequent usage of TRBV5. Based on the resemblances among these clones overall, we hypothesized that they recognize a shared antigen. Since they were also particularly expanded in treated mice, we chose to focus on this set of clones for antigen identification.

Prominent T cell clones recognize an endogenous retrovirus peptide presented by multiple tumor types

To identify the cognate antigen of these TILs, we first tested whether cells expressing the identified TCRs selectively recognized tumor cell lines and if that recognition correlated with expression of melanocyte tissue lineage antigens. Murine CD8⁺ 58^{-/-} T cell hybridomas were transduced with the 7PPG2 and 7PPG4 TCRs, two representative TIL sequences sharing TCR alpha chain homology but expressing distinct TCR beta chains. The transduced T cell lines were then tested for activation as measured by IL-2 secretion upon challenge by a panel of tumor cell lines pre-treated with IFN- γ to upregulate class I MHC expression (**Figure 2A, Supplementary Figure 2A**). As a positive control, 58^{-/-} T cells transduced with the 2C TCR were challenged via coculture assay with B16.SIY cells, a B16F10 melanoma line modified to express the 2C cognate antigen SIY (17). We found that 7PPG2- and 7PPG4-transduced 58^{-/-} T cells were activated following co-culture with B16F10 and B16.SIY cells but not TC-1 cells, a transformed mouse lung epithelial cell line (**Figure 2A**). Intriguingly, 58^{-/-} T cells

transduced with 7PPG2 and 7PPG4, but not 2C, also recognized MC-38 cells, a murine colon adenocarcinoma cell line (**Figure 2A**). Therefore, 7PPG2 and 7PPG4 TCR-transduced 58^{-/-} T cells showed a degree of antigen selectivity that did not appear in only melanocyte-specific contexts.

A recent study examining the humoral immune responses in AIPV-treated mice noted that the majority of the induced antibody response targeted an endogenous retroviral envelope glycoprotein from murine leukemia virus, MLVenv (18). We therefore hypothesized that the collection of homologous T cell clones expanded following AIP therapy also recognized an epitope from MLVenv. Indeed, the reactivity pattern we observed in our initial screening (**Figure 2A**) closely matched Kang et al.'s finding that B16F10 and MC-38 cells expressed MLVenv while TC-1 cells did not (18).

To further investigate the potential that the dominant anti-tumor response after AIP treatment recognized an endogenous retrovirus (ERV)-derived epitope, we tested several additional cancer cell lines with different levels of ERV expression. It has been shown that ERV transcript numbers can be increased by treating cells with a DNA methyltransferase inhibitor (DNMTi) (19), which we confirmed by treating cells with decitabine and measuring MLVenv transcript level (**Supplementary Figure 2B**). The KP2677 autochthonous lung adenocarcinoma line was found to activate 7PPG2- and 7ELG1-transduced 58^{-/-} T cells with or without DNMTi treatment, while KP-E93-12, 1233 T4, KP-7B, and KP-E85 CC1 W24 cells only activated 7PPG2- and 7ELG1-transduced 58^{-/-} T cells after treatment with decitabine to increase ERV transcript levels (**Supplementary Figure 2C**).

With these data supporting the recognition of an ERV peptide by these T cell clones, we hypothesized that the previously identified MLVenv peptide KSPWFTTL, often referred to as p15E, could be the recognized T cell antigen presented by the class I MHC H-2K^b (20). We tested for T cell activation by loading DC2.4 cells with p15E peptide and then coculturing with TCR-transduced 58^{-/-} T cells. SIY peptide was used as a positive control for the 2C T cell line. The 7PPG2- and 7PPG4-transduced 58^{-/-} T cell lines were activated in a dose-dependent manner by the p15E peptide while showing no activation against the SIY peptide even at highest peptide concentration (**Figure 2B**). To further confirm binding, we performed surface plasmon resonance to determine affinity between the pMHCs and several different TCRs. The p15E-K^b complex bound TCRs 7PPG2, 7PPG3, 7PPG4, and 7ELG1 with K_D values ranging from 20 to 40 μM, within the range of typical affinities observed for TCR-pMHC binding (**Figure 2C**) (21).

p15E-specific T cells dominate among activated, proliferating cells following AIP therapy

Once we had identified p15E as the antigen recognized by some of the most expanded T cell clones in mice treated with AIP therapy, we further investigated the antigen-specific immune response elicited by AIP treatment. Mice were treated with an updated dosage schedule of the AIP therapy, and p15E-tetramer⁺ CD8⁺ T cells were sorted out from TILs (**Supplementary Figure 3A**). We performed single-cell paired TCR and RNA sequencing of tetramer-positive and tetramer-negative CD8⁺ T cells from AIP-treated mice. In sum, we obtained data for 4,605 tetramer-positive and 3,217 tetramer-negative cells. Strikingly, cells in the tetramer-positive fraction demonstrated substantial levels of clonal expansion relative to cells in the tetramer-negative fraction, indicating that the T cell response to B16F10 tumors undergoing AIP treatment leads to expansion of several clonotypes in response to the p15E antigen (**Figure 3A**).

Unsupervised analysis of the gene expression of these cells generated five genotypic clusters (**Figure 3B**), with tetramer-positive cells primarily found in clusters 1, 4, and 5 (**Figure 3C**). Clusters 2 and 3 preferentially expressed *Ccr7* and *Sell* and exhibited little clonal expansion, suggesting that these clusters primarily consist of naïve or bystander T cells (**Figure 3D-F**). Cluster 4 demonstrated an intermediate level of clonal expansion and expressed markers associated with an effector population, including *Klrg1*, *Cxcr3*, and *Itga4* (**Figure 3D-F**). Both Clusters 1 and 5 were highly clonally expanded and expressed high levels of cytotoxic markers, including *Ifng*, *Gzmb*, *Pfn1*, as well as exhaustion markers, such as *Pdcd1*, *Havcr2*, and *Lag3* (**Figure 3D-F**). In addition to these markers, cluster 5 expressed markers associated with proliferation and cell cycle progression, including *Mki67* and *Top2a* (**Figure 3F**). Cells in the tetramer-positive fraction were 19.7-fold enriched for proliferating cells (Cluster 5) and 21.7-fold enriched for exhausted cells (Cluster 1), indicating that a substantial fraction of CD8⁺ T cells involved in response to B16F10 tumors after AIP treatment are specific for the p15E antigen.

We also analyzed TCR sequences associated with the p15E antigen. In sum, we detected a total of 61 clonally expanded lineages comprised of three or more cells that were at least five-fold enriched in frequency in the tetramer-positive fraction relative to the tetramer negative-fraction. Of these sequences, 37.7% (23 of 61) exhibited usage of the *Traj7* gene segment (**Supplementary Figure 3B**). Among these sequences with *Traj7* usage, we observed a preference for pairing with *Trbv5*, *Trbv16*, and *Trbv20* (**Supplementary Figure 3C**), and we identified four sequences with a PPG motif in the beta chain and two sequences with a LELGG motif in the beta chain (**Supplementary Figure 3D**), consistent with data obtained from single-cell sorting of T cells. We also identified three sequences with an SWT motif in the beta chain, indicating that other TCR motifs may encode specificity of the p15E epitope (**Supplementary Figure 3D**). In sum, these results demonstrate that the p15E peptide is a dominant T cell antigen in the B16F10 model and that a variety of motifs, in addition to the TRAJ7 alpha chain, can encode specificity for p15E.

Prophylactic vaccination against p15E does not induce strong T cell responses or delay tumor growth

Given the immunodominance of the p15E antigen following AIP therapy, we next tested whether prophylactic vaccination could delay B16F10 tumor growth. We tested three long peptide vaccine formats with enhanced immunogenicity that have been previously investigated: mouse serum albumin (MSA), transthyretin (TTR), and amphiphile peptide fusions (16,22,23). In each case, a long peptide centered around the p15E 8mer (EGLFNKSPWFTTLSTIMG) was used as the antigenic sequence. C57BL/6 mice were primed with an initial dose of vaccine supplemented by lipo-CpG adjuvant. Mice then received booster vaccines at 14 and 28 days (**Figure 4A**). Intracellular cytokine staining (ICS) of peripheral blood was performed to assess T cell reactivity to p15E at days 21 and 35. The amphiphile vaccine resulted in the highest T cell reactivity, averaging 2.5% among CD8⁺ T cells by day 35 (**Figure 4B**). Although this reactivity was statistically significant, it was modest when compared to amphiphile vaccination with some common model antigens, which can reach upwards of 30% (22,24). Upon tumor challenge with 3×10⁵ B16F10 cells, no delay in tumor growth (**Figure 4C**) or significant increase in survival (**Figure 4D**) was observed.

Yeast display of pMHCs allowed identification of mimotopes with increased functionality

We hypothesized that the relatively low T cell response and lack of effect on tumor growth may be due to immune tolerance or thymic deletion caused by low level expression of ERVs in healthy tissues, as has been previously described for self-antigens (25–30). To overcome this limitation, we hypothesized that p15E mimotopes may more potently induce specific T cell activation.

To identify mimotope peptides with increased affinity for the T cell clones, we diversified putative TCR contact residues of the p15E peptide (positions 1, 4, 6, and 7) based upon previously solved H-2K^b structures (31,32) and created a library of peptides displayed by H-2K^b on yeast (**Supplementary Figure 4A**). Selections were performed on this library using five of the TCRs identified in this study (**Table 1**) and were tracked via next-generation sequencing of enriched yeast following each round of selection. Heat maps were created to show amino acid preference at each position based on read counts of peptides in the sequencing data (**Figure 5A, Supplementary Figure 4B-D**). Generally, position 4 converged to the wild type amino acid tryptophan, with the exception of selection with 7DLG1 which also tolerated tyrosine. Position 1 preferred valine or the wild type lysine, while positions 6 and 7 had more flexibility in amino acid preference depending on the TCR.

We next chose a subset of mimotopes identified from 7PPG2, 7PPG4, and 7ELG1 selections that were either enriched during selections or identified based on the preferences revealed in the heat maps. We tested these mimotopes for their ability to activate their cognate TCR-transduced T cell lines. Several of the mimotopes were able to induce higher IL-2 production in the T cell lines than stimulation with p15E (**Supplementary Figure 5A-C**). The 7PPG2 and 7PPG3 T cells were often more potently activated by peptides with a valine at position 1. 7PPG4 in particular was strongly activated by three mimotopes, with about ten-fold changes over p15E. Based on these results, two mimotopes were chosen for further characterization: 7PPG2-mim6 (VSPWFNTL) and 7PPG4-mim2 (KSPWFITL).

In dose response experiments, each of these mimotopes induced activation much more potently than p15E (**Figure 5B**). To determine if changes to the peptide were affecting pMHC stability, we performed differential scanning fluorimetry on each of the refolded pMHCs. Melting temperatures of the mimotope complexes were within a few degrees of the p15E-K^b melting temperature, indicating similar stability (**Supplementary Figure 5D**). We then performed surface plasmon resonance experiments to compare the binding affinities of p15E, 7PPG2-mim6, and 7PPG4-mim2 displayed by H-2K^b for TCRs 7PPG2 and 7PPG4. Although 7PPG2-mim6 induced better T cell activation than p15E, the two mimotope peptides had comparable affinities for 7PPG2, ranging from 20 to 40 μ M (**Figure 5C**). In contrast, 7PPG4-mim2 had five-fold higher affinity for 7PPG4 than p15E, 5 μ M compared to 26 μ M (**Figure 5C**). Based on the increased T cell activation induced by both mimotopes and the higher affinity of 7PPG4-mim2, we hypothesized that vaccination with these peptides would induce better T cell responses to p15E and could result in tumor delay.

Mimotope vaccine-induced T cells can specifically kill p15E-pulsed cells

Following characterization of the mimotope candidates, we performed an *in vivo* killing assay to assess whether vaccination with the mimotopes would result in the expansion of T cells able to kill target cells presenting the p15E antigen. This study consisted of a control group of mice receiving adjuvant only, a p15E amphiphile vaccine group, a group receiving both mimotope vaccines, and an OVA amphiphile vaccine group. Mice received initial vaccines on day 0 and boosts on days 14 and 28 (**Figure 6A**). On day 35, blood samples were taken for ICS to assess antigen-specific T cell

expansion, with mice receiving injections of a mixture of dye-labeled peptide-pulsed donor splenocytes (**Figure 6B**). The following day, spleens were removed from experimental mice and processed to assess the remaining populations of dyed cells.

This assay showed that mimotope vaccinated mice were able to specifically kill the p15E-pulsed splenocytes (**Supplementary Figure 6A**), resulting in a very low fraction of p15E-pulsed cells remaining (**Figure 6C**). Similarly, OVA vaccinated mice were able to kill the OVA-pulsed splenocytes, resulting in a high fraction of p15E-pulsed cells remaining. The p15E vaccinated group showed little difference in fraction of p15E-pulsed cells compared to the control group, indicating that no significant killing of either population of peptide-pulsed splenocytes occurred. In terms of reactivity to the targeted antigen, ICS revealed ~5% reactivity to p15E in the group vaccinated with both mimotopes and 20% reactivity to OVA in the OVA vaccinated group (**Supplementary Figure 6B**).

Vaccination with mimotope peptides increases T cell response to p15E but does not consistently extend survival following tumor challenge

We next sought to assess whether the T cell response induced by mimotope vaccination resulted in tumor protection. For this study, we compared the function of each mimotope individually or the combination of both mimotopes to p15E in a prophylactic vaccination setting. Mice were primed with an initial dose of 5 nmol total amphiphile vaccine (representing 2.5 nmol of each peptide for the group that received both mimotope vaccines) and 1.24 nmol lipo-CpG adjuvant. Booster vaccines were administered at days 14 and 28, with blood drawn for ICS at days 21 and 35 to assess T cell reactivity (**Figure 7A**).

On day 21, the fraction of CD8⁺ T cells was significantly higher in groups that received any mimotope vaccine as compared to the control or p15E vaccine groups (**Figure 7B**). This disparity increased further by day 35 for 7PPG2-mim6 and both mimotope vaccine groups, indicating that vaccination against the mimotopes was successful at inducing the proliferation of CD8⁺ T cells.

To determine reactivity to specific peptides, blood samples were stimulated with either p15E, 7PPG2-mim6, or 7PPG4-mim2 peptides and assessed for cytokine production via ICS. For mimotope vaccinated groups, there were very high responses to the peptides matched to the vaccine that a group received, ranging from ~25 to 40% of CD8⁺ T cells (**Supplementary Figure 7A, 7B**). Consistent with the increased affinity of 7PPG4 TCR for 7PPG4-mim2 relative to p15E, 7PPG4-mim2 elicited the greatest response, with 40% of CD8⁺ T cells reacting to stimulation at day 21 (**Supplementary Figure 7B**). Mice vaccinated with 7PPG4-mim2 displayed some cross reactivity to 7PPG2-mim6 stimulation, but in contrast, there was minimal reactivity to 7PPG4-mim2 in the group vaccinated with 7PPG2-mim6.

Following stimulation of blood samples with p15E, we found that at both days 21 and 35, the p15E vaccinated group did not show any significant reactivity compared to the control group which received only adjuvant (**Figure 7C**). However, the groups vaccinated with mimotopes displayed higher responses to p15E, in particular the 7PPG4-mim2 vaccinated group which reached 40% reactivity at day 35 (**Figure 7C**). The group vaccinated with both mimotopes generally performed similarly to the 7PPG2-mim6 vaccinated group and worse than the 7PPG4-mim2 vaccinated group when examining reactivity to p15E stimulation.

Six weeks after initial prime (**Figure 7A**), mice were challenged with 1×10^5 B16F10 melanoma cells on the right flank. Tumors grew at a similar rate in the control and p15E vaccinated groups (**Figure 7D**), resulting in identical survival curves for these two groups (**Figure 7E**). For the individual mimotope vaccine groups, tumors tended to grow more slowly (**Figure 7D**), and these mice had a modest, statistically significant increase in survival (**Figure 7E**). The group vaccinated with both mimotopes contained several mice with delayed tumor growth (**Figure 7D**), although their survival was only modestly different than the p15E vaccinated group (**Figure 7E**). Overall, we did not observe any weight loss over 10% in the period post-tumor challenge (**Supplementary Figure 7C**), indicating that the vaccines were well tolerated. In a second independent experiment, the mimotope vaccinated mice similarly had significantly higher quantities of CD8⁺ T cells and improved reactivity to p15E compared to control and p15E vaccinated groups (**Supplementary Figure 8A-B**). Following tumor challenge, we observed a statistically significant increase in survival for the group receiving both mimotope vaccines, with one mouse completely rejecting the tumor, but no such increase for the two individual mimotope vaccinated groups (**Supplementary Figure 8C**). Thus, we conclude that mimotope vaccination increases the quantity of T cells responsive to p15E but may only provide a modest protective response.

Discussion

Determining the antigen reactivity of T cells expanded in an anti-tumor immune response can help inform the development of immunotherapies. Thus, we sequenced the TCRs of activated CD8⁺ TILs from B16F10 melanomas and found the T cell response to be oligoclonal in both treated and untreated mice. Other groups have characterized similarly oligoclonal responses for TILs (33,34). Interestingly, there were three TRAV regions represented amongst these clones, but only one J region, TRAJ7. The functionality of TRAJ7 is listed as ORF on IMGT (35), indicating that the gene has an open reading frame (ORF) but has not been functionally described. However, as this region is highly prevalent in our data and we demonstrate proper function of these TCRs, we propose that TRAJ7 is a functional gene. Overall, such similarities in CDR3 sequences are not unheard of; in fact, it has been suggested that public TCRs are prevalent and formed through convergent recombination, especially when there is minimal addition of random nucleotides as observed here (36–39).

We identified the p15E peptide (KSPWFTTL) from the envelope glycoprotein of murine leukemia virus as the antigen recognized by the tumor-reactive T cells expressing homologous TCRs. ERVs arose from retroviral infection of germline cells that resulted in integration into the genome throughout evolution (40). Retrovirus-like elements make up 8–10% of the human and mouse genomes (41). In contrast to the majority of human ERVs, many ERVs in mice remain active (42). C57BL/6 mice carry a single endogenous ecotropic provirus known as *Emv-2* on chromosome 8 (43,44), but it is defective due to a mutation in the reverse transcriptase (45). In healthy tissues, ERV expression is regulated primarily through DNA methylation but also through restriction factors and other epigenetic mechanisms (46–49). In many tumors, however, ERVs are overexpressed (50,51), and *de novo* copies may emerge through recombination of ecotropic and non-ecotropic ERVs, such as melanoma associated retrovirus (MelARV) in B16 tumors (44,52–55).

p15E was previously identified as a T cell antigen (20), with groups demonstrating the expansion of p15E-specific T cells from naive mice and the targeting of p15E in adoptive cell therapy or in vaccine paradigms (20,56–58). A number of previous studies tracking p15E-specific T cells provide evidence for just how dominant p15E can be in anti-tumor immune responses, even in cases in which another

Identification of cross-reactive mimotopes

antigen is targeted (33,59–61). Our data also support the dominance of the p15E antigen in the case of a combination therapy undirected towards a particular antigen. This recognition appears to utilize highly conserved TCR motifs that can serve as a sequence-based readout of ERV responses. Despite its dominance, our results suggest that even robust p15E-specific responses are not sufficient to induce protective anti-tumor immunity, and it has been previously shown that p15E responses are not necessary for an effective anti-tumor response (61). Tolerance developed against ERVs presents an obstacle to achieving potent anti-tumor immune responses when targeting non-mutated self-antigens such as p15E (62–65), motivating our use of mimotopes to enhance the T cell response.

Characterization of the mimotopes 7PPG2-mim6 and 7PPG4-mim2 revealed their ability to more potently activate their cognate TCRs, but only 7PPG4-mim2 had increased affinity for its TCR compared to p15E. The fact that 7PPG2-mim6 improves potency without increasing affinity for the TCR is notable, but the decoupling of affinity and activity is preceded in previous studies of TCR-antigen systems (10,66–68). While there is previous literature suggesting that increasing the affinity of mimotopes may lead to dysfunction *in vivo* (9), 5 μ M is lower than the affinities tested in that case, and 7PPG4-mim2 did not show evidence of deleterious autoreactivity in any *in vivo* studies.

Much of the existing work studying ERVs in mice involves the immunodominant ERV antigen AH1, a peptide from the gp70 surface unit of MLVenv in BALB/c mice (69). AH1 is displayed by the class I MHC H-2L^d in CT26 tumors, and it has been successfully targeted in vaccine and adoptive transfer paradigms (57,58,69–71). Additionally, the efficacy of AH1 mimotopes has been well established, with studies demonstrating increased affinities for TCRs, use in prophylactic vaccinations, and cross reactivity within T cell repertoires (8,9,13,14,72–74). Thus, there has been clear demonstration of the benefit of using AH1 mimotopes to improve anti-tumor immunity in BALB/c mice, but to our knowledge, no such identification of p15E mimotopes applicable to C57BL/6 mice. We have demonstrated here the identification of two mimotopes of ERV peptide p15E relevant to multiple tumor types in C57BL/6 mice. The existence of immunodominant responses targeting an ERV epitope in C57BL/6 models treated with immunotherapies such as ICB is particularly notable given how widely used these models are used by cancer biologists and immunologists. Further work is necessary to test these mimotope vaccines in combination with checkpoint inhibitors, MLVenv-targeting antibodies, DNMTis, or other therapeutic modalities, in hopes that they can further improve responses beyond those observed via prophylactic vaccination alone (18,19,75,76).

It should be noted that there are caveats to using mouse models to study ERVs as tumor antigens. While infectious copies of recombined ERVs are common in mice (44,52–55,77), human ERVs (HERVs) so far appear to be inactive (42), which could alter the kinetics of antigen expression. Nevertheless, HERVs have long been studied in association with cancer (78–81). Expression of HERVs has been shown to be a prognostic indicator and to be associated with the response to immunotherapy in renal cell carcinoma and other cancers (82–84). For melanoma specifically, studies have shown elevated HERV-K expression, the production of viral particles, and the presence of HERV-specific antibodies in patient sera (85–87). Further, Schiavetti et al. reported the identification of an HERV-K antigen presented by HLA-A2 and recognized by CD8⁺ T cells in melanoma patients (88).

There is substantial evidence that HERVs can be therapeutically targeted as TAAs in some cancers. Chimeric antigen receptor (CAR) T cells targeting HERVs have been developed for breast cancer and

melanoma (89,90), and adoptive transfer of HERV-E specific T cells is being evaluated in a phase I clinical trial for renal cell carcinoma (91). Finally, in a study particularly relevant to the translational potential of ERV-targeting vaccines, Sacha et al. vaccinated rhesus macaques with simian ERV-K Gag and Env and found that vaccination induced T cell responses with no adverse effects or induction of autoimmune disease (92). These studies, in conjunction with our results, suggest that both natural and engineered anti-ERV immune responses present potential novel avenues towards anti-cancer immunotherapies.

Materials and Methods

Mice

4-6 week old female C57BL/6 mice were obtained from the Jackson Laboratory (C57BL/6J) or Taconic (C57BL/6NTac) and used in studies beginning at 6-8 weeks of age. All animal work was conducted under the approval of the MIT Division of Comparative Medicine in accordance with federal, state, and local guidelines.

Cells and media

HEK293-T cells were obtained from ATCC. B16F10 and DC2.4 cells were gifts from the Irvine lab. B16.SIY cells were a gift from the Spranger lab. MC-38 and TC-1 cells were gifts from the Wittrup lab. KP lines were gifts from the Jacks lab. CD8⁺ 58^{-/-}, Sf9, and Hi5 cells were gifts from the Garcia lab.

HEK 293-T, B16F10, B16.SIY, and MC-38 cells were cultured in Dulbecco's Modified Eagle's Medium (ATCC) supplemented with 10% fetal bovine serum (FBS, R&D Systems), 100 U/mL penicillin (Thermo), and 100 µg/mL streptomycin (Thermo). TC-1, DC2.4, and 58^{-/-} lines were cultured in RPMI-1640 media (ATCC) supplemented with 10% FBS, 100 U/mL penicillin, and 100 µg/mL streptomycin. All mammalian cell lines and assay cultures were maintained at 37°C and 5% CO₂. All cells were frequently tested and confirmed negative for mycoplasma contamination. B16F10 cells used for tumor challenge studies also tested negative for rodent pathogens.

Sf9 cells were cultured in Sf-900 III SFM (Gibco) supplemented with L-glutamine, 10% FBS (R&D Systems), and 20 µg/mL gentamicin sulfate (Lonza). Hi5 cells were cultured in Insect-XPRESS (Lonza) supplemented with 10 µg/mL gentamicin sulfate (Lonza). Insect cell lines were maintained at 27°C with shaking at 120 rpm.

Flow cytometry

Antibodies to Myc (clone 9B11) and Flag (clone D6W5B) were purchased from Cell Signaling Technology. Antibodies to human β₂M (clone 2M2), mouse TCR β chain (clone H57-597), mouse H-2K^b/H-2D^b (clone 5041.16.1), mouse IFN-γ (clone XMG1.2), mouse TNF-α (clone MP6-XT22), mouse CD8α (clone 53-6.7), and mouse CD16/32 (Fc block, clone 93) were purchased from Biolegend. Other reagents used include Zombie Aqua Viability Dye (Biolegend), CellTrace CFSE and CellTrace Violet (Invitrogen). Samples were run on an Accuri C6 (BD), LSRII (BD), or Cytoflex (Beckman Coulter) and analyzed in the Accuri software or FlowJo v10. Samples were run in FACS buffer (phosphate-buffered saline (PBS) with 2 mM EDTA and 0.5% bovine serum albumin (BSA)).

406 ***T cell sorting and sequencing following AIP therapy***

407 Mice were inoculated with 10^6 B16F10 cells subcutaneously on the right flank. On days 8 and 15,
408 mice received AIP therapy (TA99, extended half-life IL-2, and anti-PD-1) as previously described (16).
409 On day 21, mice were euthanized, single cell suspensions were generated from tumors, and red
410 blood cells were lysed. IFN- γ secreting cells were labeled using the mouse IFN- γ secretion assay
411 (Miltenyi Biotec) and then stained for viability and CD8. Splenocytes stimulated with 10 ng/mL PMA
412 and 10 μ g/mL ionomycin were used as a positive control. IFN- γ^+ CD8 $^+$ T cells were sorted into RT-
413 PCR buffer in 96 well plates, one cell per well, on a FACSARIA (BD).

414 Single-cell sequencing of TCRs was performed by nested reverse-transcription polymerase chain
415 reaction (RT-PCR) using previously published primer sets (93,94). RT-PCR was performed using One
416 Step RT-PCR kits (Qiagen) and a mixture of TRAV-, TRBV-, TRAC-, and TRBC-specific primers. Nested
417 PCR was then performed with a second set of TCR alpha- and beta-specific primers. A third PCR step
418 was then performed separately for alpha and beta chains to add group, plate, column, and row DNA
419 barcodes, as well as P5 and P7 sequences for paired end NGS. Alpha and beta chain PCR products
420 were then pooled separately, run on 1% agarose gels, and purified by gel extraction (GeneJET PCR
421 Gel Extraction Kit, Thermo). Samples were sequenced at the MIT BioMicroCenter using Illumina
422 MiSeq 500nt paired-end kits.

423 TCR sequencing data was analyzed using a combination of in-house and publicly available programs.
424 Contigs were assumed from paired end reads by Flash (95) and an in-house program was used to
425 demultiplex sequences and segregate alpha and beta chain sequences. Unique sequences were
426 then collapsed using MIGEC (96) and sequences were fed through HighV-Quest (97) to assess VDJ
427 usage and CDR3 sequence. Paired chain sequences were assembled based on demultiplexed read
428 barcodes. TCRs in separate wells with identical CDR3 sequences and VDJ usages were identified as
429 members of a clonal lineage. Any contaminating sequences from previous sequencing runs were
430 manually identified through comparison of exact nucleotide sequences and examination of
431 sequences which appeared in wells that intentionally did not contain T cells.

432 ***p15E-specific T cell sorting, sequencing, and phenotyping***

433 Mice were inoculated with 10^6 B16F10 cells subcutaneously on the right flank. At day 8, mice
434 received AIP therapy, followed by ICB every three days thereafter, as previously described for 1x
435 AIP therapy (98). On day 26, mice were euthanized. Single cell suspensions were generated from
436 tumors and spleens. Pan-T cell isolations were performed using an EasySep mouse T cell isolation kit
437 (Stem Cell), and then T cells from three tumors were pooled and stained with Zombie Aqua, Fc
438 block, 5 nM p15E-tetramer (produced in-house), CD3, and CD8. Splenocytes were used as controls
439 for sorting.

440 ***Single-cell RNA sequencing***

441 Tetramer-positive and tetramer-negative CD8 $^+$ T cells were processed for single-cell RNA
442 sequencing using the Seq-Well platform with second strand chemistry (99,100). Libraries were
443 barcoded and amplified using the Nextera XT kit (Illumina) and were sequenced on the Illumina
444 Novaseq.

445 ***Analysis of single-cell gene expression***

446 Raw read processing was performed as in Macosko et al (101). Briefly, sequencing reads were
447 aligned to the mm10 reference genome, collapsed by unique molecular identifier (UMI) and
448 aggregated by cell barcode to obtain a gene expression matrix of cells versus genes. Barcodes with
449 under 300 unique genes detected were then excluded from analysis. The data was then log-
450 normalized by library size and variable genes were selected using the FindVariableGenes function in
451 Seurat. The ScaleData function in Seurat was then used to scale the data to unit variance using a
452 Poisson model and to regress out the number of genes detected per cell (102). The RunPCA function
453 was then used to perform principal component analysis, and the top 20 principal components were
454 used to generate a UMAP with the RunUMAP function. Clusters were then determined with the
455 FindClusters function.

456 ***Recovery and analysis of TCR sequences from single cell libraries***

457 TCR sequences were recovered from TCR libraries according to Tu et al. (103). Briefly, biotinylated
458 baits for TRBC and TRAC were used to enrich TCR transcripts from barcoded whole-transcriptome
459 amplification product. This product was then further amplified using mouse V-region primers and
460 prepared for sequencing using Nextera sequencing handles. Libraries were sequenced on an
461 Illumina Miseq using 150 nt length reads. CDR3 sequences were obtained as described previously.

462 ***Peptides***

463 Crude peptides used for T cell activation experiments and pMHC refolds were obtained from the
464 Proteomics Core of the Swanson Biotechnology Center. Peptide sequences are as follows: p15E:
465 KSPWFTTL, 7PPG2-mim6: VSPWFNTL, 7PPG4-mim2: KSPWFITL, SIY: SIYRYGYL, OVA: SIINFEKL.

466 ***T cell activation assays***

467 T cell line generation: For creation of T cell lines, TCR alpha chain was linked to TCR beta chain by a
468 P2A sequence, followed by EGFP fluorescent protein sequence, in the MP71 retroviral vector. 80%
469 confluent HEK293-T cells were transfected with 2 µg of TCR plasmid and 1 µg pCL-Eco helper
470 plasmid with 6 µg (3× DNA mass) PEI (Santa Cruz Biotech) to create retrovirus. 2 days later, the
471 supernatant was then used to transduce CD8⁺ 58^{-/-} cells with 0.8 µg/mL polybrene (Santa Cruz
472 Biotech). Cells were spininfected at 1000×g and 32°C for 1.5 hours. 2 days later, transduction was
473 assessed by expression of EGFP and by staining with an antibody against murine TCR β chain. If
474 necessary, cells were sorted on EGFP on a FACS Aria (BD) to obtain a >95% transduced population.

475 Tumor cell co-culture: Recombinant murine IFN-γ (Peprotech) was added to a working
476 concentration ≥500 U/mL (1:1000 from a 0.1 mg/mL stock solution) to tumor cell lines 24 hours
477 before co-culture setup to increase MHC expression. 25,000 T cells and tumor cells at an E:T ratio of
478 1:1, 2:1, 5:1, or 10:1 per well were co-cultured in 200 µL RPMI complete media in 96 well plates.

479 DC co-culture: 25,000 DC2.4 cells per well were incubated with various concentrations of peptide in
480 100 µL RPMI complete media for 2-3 hours before the addition of T cells. 25,000 T cells per well
481 were added in 100 µL RPMI complete media in 96 well plates.

482 After 24 hours, plates were spun down at 500×g for 5 minutes, and 2×100 µL samples of
483 supernatant were saved and frozen at -80°C. T cell activation was assessed using mouse IL-2 ELISA

484 kits (Invitrogen), with samples diluted 1:2 - 1:20 for comparison to the standard curve. Absorbance
485 values were measured with a Tecan Infinite m200 Pro plate reader.

486 ***RT-qPCR***

487 Total RNA was collected from cultured cells treated with 100 nM 5-aza-2'-deoxycytidine
488 (decitabine; Sigma) or splenocytes from a naïve C57BL/6 mouse using NucleoSpin RNA Plus (Takara).
489 RNA was reverse transcribed with SuperScript III RT and random primers (Invitrogen) to synthesize
490 first-strand cDNA. RT-qPCR was performed with Luna Universal qPCR reagent (NEB). eMLV env was
491 detected with 5'-AGGCTGTTCCAGAGATTGTG-3' and 5'-TTCTGGACCACCACATGAC-3' and 18S rRNA
492 was detected with 5'-GTAACCCGTTGAACCCATT-3' and 5'-CCATCCAATCGGTAGTAGCG-3' on Roche
493 LightCycler 480 II (104,105).

494 ***TCR expression and purification***

495 Recombinant soluble TCRs used for yeast library selections and surface plasmon resonance
496 experiments were produced using a baculovirus expression system in Hi5 insect cells. TCR alpha
497 chain extracellular domain sequences were cloned into pAcGP67a vector containing a 3C protease
498 site (LEVLFGQP) followed by an acidic leucine zipper, AviTag biotinylation site (GLNDIFEAQKIEWHE),
499 and poly-histidine tag (6xHis). TCR beta chain extracellular domain sequences were cloned into
500 pAcGP67a vector containing a 3C site followed by a basic leucine zipper and poly-histidine tag. 2 µg
501 of each plasmid was transfected into SF9 insect cells with BestBac 2.0 linearized baculovirus DNA
502 (Expression Systems) using Cellfectin II reagent (Invitrogen). SF9s were then infected with 1:1000
503 primary transfection supernatant to amplify the virus. Titration of alpha and beta chain viruses was
504 performed to identify the optimal ratio of the two viruses for heterodimer formation. Protein was
505 then produced by large scale infection of Hi5 cells. Secreted protein was purified using HisPur Ni-
506 NTA resin (Thermo) for immobilized metal affinity chromatography (IMAC) and biotinylated
507 overnight at 4°C using biotin (Avidity), ATP, and BirA ligase. Proteins were further purified by size
508 exclusion chromatography via an S200 column on an AKTApure FPLC (Cytiva). Biotinylation
509 efficiency was assessed by adding streptavidin (ThermoFisher) to ~2 µg of protein and running an
510 SDS-PAGE gel. Aliquots of biotinylated TCR were stored in HBS with 20% glycerol at -80°C.

511 ***pMHC protein expression and purification***

512 The following were separately cloned into bacterial expression vector pet28a: the extracellular
513 domains α_1 , α_2 , and α_3 of heavy chain H-2K^b plus an AviTag biotinylation site and poly-histidine tag,
514 and human β 2M plus a poly-histidine tag. Inclusion bodies for H-2K^b and β 2M were generated in
515 BL21 *E. coli* and denatured in 8 M urea and 6 M guanidine hydrochloride. Excess peptide and β 2M
516 were injected into MHC refolding buffer (100 mM Tris, 400 mM L-arginine hydrochloride, 2 mM
517 EDTA, 0.5 mM oxidized glutathione, 5.0 mM reduced glutathione, 0.2 mM PMSF). H-2K^b was
518 injected one hour later at a 1:1 mass ratio with β 2M, and the solution was incubated for 24 hours at
519 4°C. Complexes were desalted by dialysis in deionized water at room temperature over 2 days and
520 then purified using IMAC or anion exchange followed by size exclusion chromatography on an
521 AKTApure FPLC (Cytiva). For SPR experiments, complexes were purified using an S200 column
522 followed by an S75 column and used fresh. For pMHC to be used in formation of pMHC tetramers,
523 complexes were biotinylated overnight at 4°C using biotin (Avidity), ATP, and BirA ligase and then
524 purified using an S200 column; monomers were stored in HBS at -80°C. pMHC tetramers were

created by adding pMHC monomer to tetrameric AlexaFluor647-conjugated streptavidin (produced in-house as previously described) at a 6:1 ratio and incubating for 30 minutes at 4°C (106).

Surface plasmon resonance

Steady-state surface plasmon resonance experiments were performed with a Biacore T200 instrument. TCRs were immobilized at 1100 – 2400 response units on Series S CM5 sensor chips (Cytiva) by amine coupling. pMHC was injected as analyte with a concentration range of 0.35 – 266 µM and a flow rate of 10 µL/min at 25°C. Samples were in HBS-EP (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% v/v Surfactant P20) or HBS-EP+ buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.05% v/v Surfactant P20). Data was fit with GraphPad Prism 9 one site specific binding model and normalized to R_{max} .

Differential scanning fluorimetry

Differential scanning fluorimetry (DSF) was performed using a CFX384 RT-PCR instrument (Bio-Rad). Excitation and emission wavelengths were 587 and 607 nm, respectively. Samples were at 10 µM pMHC concentration with 10× SYPRO Orange (Invitrogen) in 10 µL HBS-EP+ buffer in a 386 well plate. The temperature range was 20 to 95°C with a scan rate of 1°C per minute. Measurements were performed on triplicate samples.

Vaccine studies

MSA and TTR long peptide fusions were produced in house by the Wittrup lab as previously described (23). Long peptide-amphiphile fusion vaccines were obtained from Northwestern University Peptide Synthesis Core (p15E and mimotopes) or produced in house by the Irvine lab as previously described (OVA amph) (16,22). Lipo-CpG was produced in house by the Irvine lab as previously described (16,22). 5 nmol of vaccine and 1.24 nmol of lipo-CpG per injection were used in a volume of 100 µL PBS, sterile filtered, and injected subcutaneously at the tail base, 50 µL per side, using 31G insulin syringes. Mice were primed and then boosted at 2 and 4 weeks following prime (n=5 per group).

Vaccine sequences are as follows:

MSA-p15E: MSA-EGLFNKSPWFTTLISTIMG

TTR-p15E: TTR-EGLFNKSPWFTTLISTIMG

p15E amph: DSPE-PEG2000-CEGLFNKSPWFTTLISTIMG

7PPG2-mim6 amph: DSPE-PEG2000-CEGLFNKSPWFNTLISTIMG

7PPG4-mim2 amph: DSPE-PEG2000-CEGLFNKSPWFITLISTIMG

Intracellular cytokine staining (ICS)

One week following each vaccine boost, blood samples were drawn retro-orbitally from each mouse. 50-80 µL was used per well for stimulation with peptide, and excess blood from each group was pooled and used for a positive and negative control well per group. Red blood cells were lysed with ACK lysis buffer (Thermo), and then cells were washed once with FACS buffer. In 100 µL/well RPMI complete media, sample wells were stimulated with 10 µg/mL peptide (p15E, 7PPG2-mim6, or 7PPG4-mim2), and positive control wells were stimulated with 10 ng/mL PMA and 10 µg/mL ionomycin. Cells were stimulated for two hours before 1 uL/well brefeldin A (BD GolgiPlug) was

added, and then cells were incubated for an additional four hours. Cells were washed twice with cold PBS and then stained with Zombie Aqua 1:1000 and Fc block 1:100 in 100 μ L/well PBS for 15 minutes at room temperature. Cells were then stained with CD8 APC 1:100 in 100 μ L/well FACS buffer for 20 minutes at room temperature. Cells were fixed and permeabilized using 100 μ L/well of CytoFix/CytoPerm solution (BD) for 20 minutes at 4°C. Following two washes with Perm/Wash buffer (BD), cells were stained with IFN- γ PE and TNF- α AF488 1:75 each in 50 μ L/well Perm/Wash buffer for 30 minutes at 4°C. Following two washes with FACS buffer, samples were run on an LSR II (BD) or Cytoflex (Beckman Coulter) and data analyzed in FlowJo v10. Outliers were identified using the ROUT method with Q = 1% (GraphPad Prism 9).

Tumor challenge

Two weeks after the second vaccine boost, 10^5 B16F10 cells in 100 μ L PBS were injected subcutaneously on the right flank using 29G insulin syringes. Tumor areas were calculated by multiplying length and width taken by caliper measurement every other day beginning three days post-tumor inoculation. Mice were euthanized when tumor area exceeded 100 mm².

In vivo killing assay

Donor mice were euthanized and spleens removed. In a sterile hood, single cell suspensions were created by mashing spleens through 70 μ m mesh filters. Red blood cells were lysed using ACK lysis buffer (Thermo), and cells were washed twice with PBS. Cells were dyed with either CellTrace CFSE (Invitrogen) for 8 minutes at 2.5 μ M or CellTrace Violet (Invitrogen) for 20 minutes at 5 μ M, quenched with 10% FBS, and washed twice with lymphocyte media (RPMI-1640 with HEPES and L-glutamine, 10% FBS, 1% pen-strep, 1 $\times$ NEAA, 1 mM sodium pyruvate, and 50 μ M β -mercaptoethanol). Cell concentration was adjusted to 5×10^6 cells/mL, and 10 μ g/mL of either p15E or OVA peptide was added. Cells were incubated for two hours at 37°C in 5% CO₂. Cells were washed twice with cold PBS and mixed roughly 1:1 CFSE-dyed (p15E pulsed) to violet-dyed (OVA pulsed) cells. Around 5×10^6 cells in 100 μ L were injected per experimental mouse via the tail vein using 29G insulin syringes (n=3 per group). 24 hours later, experimental mice were euthanized and splenocytes analyzed to compare ratios of CFSE-dyed to Violet-dyed cells. Samples were run on a Cytoflex and data analyzed in FlowJo v10.

Expression of H-2K^b on the surface of yeast

Yeast displayed H-2K^b was designed as a single chain trimer cloned into the pYAL vector. The Aga2 signal peptide directly precedes the peptide, which is linked to human β 2M linked to heavy chain extracellular domains α_1 , α_2 , and α_3 linked to Aga2. Flexible glycine-serine linkers were used as follows: 3 $\times$ GGGGS between peptide and β 2M, 4 $\times$ GGGGS between β 2M and MHCI heavy chain, and a Myc epitope tag (EQKLISEEDL) followed by 3 $\times$ GGGGS between MHCI heavy chain and Aga2. The binding groove of the MHC is opened via a tyrosine to alanine mutation at position 84 of the heavy chain (Y84A) to accommodate the linker connecting the peptide to β 2M (107). The Myc tag at the C-terminal end of the pMHC construct allows antibody labeling and detection by flow cytometry. In addition, the Aga2p protein fused to the C-terminus of the pMHC construct allows association with Aga1p on the surface of yeast via disulfide bridges (108).

Plasmid was transformed into EBY100 yeast by electroporation. Yeast were grown in SDCAA media pH 4.5 for 1 day at 30°C, shaking at 250 rpm, and induced in SGCAA media pH 4.5 for 2 days at 20°C, shaking at 250 rpm (10,109). Construct expression was assessed by flow cytometry following staining with a Myc tag antibody.

Proper folding of the construct was verified using a tag enrichment experiment, in which yeast displaying p15E-K^b with a Myc tag were mixed with Flag-tagged yeast at a 1:10 ratio. Yeast were stained with Myc and Flag antibodies to verify that the Myc-tagged yeast were present at about 10%. Streptavidin beads (Miltenyi Biotec) were loaded with 400 nM 7PPG2 TCR and then incubated with the yeast mixture. The solution was selected using an LS column (Miltenyi Biotec). A sample of selected yeast was run on a flow cytometer to verify that the selected population was majority p15E-K^b yeast expressing the Myc tag, indicating proper folding of the pMHC and successful binding to the TCR.

Mimotope library design and selection

To create a mimotope library, potential TCR contact residues of the p15E peptide (KSPWF^TTLL) were randomized. The library was designed as XSPXF^XXL, where X was a position randomized using an NNK codon during polymerase chain reaction (PCR) on the MHC construct. The starting H-2K^b template did not contain a peptide so as to avoid contaminating the library with a template peptide sequence. For creation of a library of at least 10⁸ transformants, RJY100 yeast were electroporated with a 5:1 mass ratio mixture of PCR product and linearized pYAL vector. Yeast were grown for 1 day in SDCAA media at 30°C, shaking at 250 rpm, and then induced for 2 days in SGCAA media at 20°C, shaking at 250 rpm. The library was selected for 3 rounds with streptavidin beads (Miltenyi Biotec) loaded with biotinylated TCR and then for 1-2 additional rounds with tetramers of TCR and anti-AlexaFluor647 microbeads (Miltenyi Biotec). TCR tetramers were created by adding TCR to tetrameric AlexaFluor647-conjugated streptavidin (produced in-house) at a 5:1 ratio and incubating for 10 minutes at 4°C.

Yeast deep sequencing and analysis

DNA was obtained from at least 10⁷ yeast per round of selection using a Zymoprep Yeast Plasmid Miniprep II kit (Zymo Research). Primers were designed to amplify the Aga2 leader peptide through to the beginning of the β2M sequence, covering the peptide encoding region, by PCR. A second round of PCR served to add the i5 and i7 anchors for Illumina sequencing as well as a barcode unique to a given round of selection. Amplicons were sequenced by the MIT BioMicroCenter on an Illumina MiSeq using a 300nt v2 kit for 150nt paired-end reads. Paired-end reads were assembled using PANDASeq (110), clustered using CD-HIT (111), and further analyzed for amino acid prevalence at each position (weighted by read count) using an in-house program.

Statistical analysis

GraphPad Prism 9 software was used for all statistical analyses. Data with replicates is shown as the mean value with error bars showing standard error of the mean (s.e.m.). Tests, p-values, and group/replicate sizes are indicated in figure captions.

642 **Data Availability**

643 The original TCR sequencing and mimotope library selection datasets generated for this study can
644 be found in NCBI's Sequence Read Archive under BioProject ID PRJNA754131
645 (<https://www.ncbi.nlm.nih.gov/sra/PRJNA754131>). The followup p15E-specific TCR sequencing and
646 phenotyping data discussed in this publication have been deposited in NCBI's Gene Expression
647 Omnibus and are accessible through GEO Series accession number GSE196782
648 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE196782>).

649 **Conflicts of Interest**

650 B.E.G. is currently an employee of Repertoire Immune Medicines. M.E.B. is a co-founder, equity
651 holder, and advisor of Virallogic Therapeutics and Abata Therapeutics, an equity holder in 3T
652 Biosciences, and an inventor on patents related to yeast display approaches licensed to 3T
653 Biosciences. D.J.I. is a co-founder, SAB member, and equity holder in Elicio Therapeutics, and is an
654 inventor on patents licensed to Elicio Therapeutics related to the amphiphile-vaccine technology.
655 J.C.L. has interests in Honeycomb Biotechnologies, and is an inventor on patents related to the
656 SeqWell technology. M.E.B., D.J.I., and J.C.L.'s interests are reviewed and managed under MIT's
657 policies for potential conflicts of interest. The remaining authors declare that the research was
658 conducted in the absence of any commercial or financial relationships that could be construed as a
659 potential conflict of interest.

660 **Author Contributions**

661 Study conception: B.E.G. and M.E.B. Experimental design and execution: B.E.G., C.M.B., D.M.M.,
662 B.H.K., N.K.S., B.D.H., C.G.R., K.D.M., L.M., C.S.D., T.K., K.S.G., O.C.T.M., D.G., S.W. Data analysis:
663 B.E.G., D.M.M., N.K.S., B.D.H., C.G.R., P.V.H. Supervising research: J.C.L., K.D.W., D.J.I., M.E.B. Writing
664 manuscript: B.E.G. and M.E.B. Editing manuscript: all authors.

665 **Funding**

666 This work was funded by the Melanoma Research Alliance (to K.D.W. and M.E.B.). This work was
667 supported in part by the Koch Institute Support (core) Grant P30-CA14051 from the National Cancer
668 Institute. M.E.B. was additionally supported by funding from the Packard Foundation, Schmidt
669 Futures, the Pew Foundation, the V Foundation, AACR-TESARO Career Development Award for
670 Immuno-oncology Research [17-20-47-BIRN]. B.E.G. was additionally supported by the National
671 Institutes of Health Biotechnology Training Program (5T32-GM008334), the National Science
672 Foundation Graduate Research Fellowship, and the Margaret A. Cunningham Immune Mechanisms
673 in Cancer Research Fellowship Award. C.M.B. was supported by a postdoctoral fellowship from the
674 Ludwig Center at MIT's Koch Institute for Integrative Cancer Research.

675 **Acknowledgements**

676 Parts of some figures were created with BioRender.com. We thank Naveen Mehta and Christine
677 Devlin for their assistance in designing experimental reagents and the Spranger, Jacks, and Garcia
678 labs for providing cell lines and protocols. We thank Dr. Megan Burger for helpful discussion. We
679 would like to thank the Koch Institute's Robert A. Swanson (1969) Biotechnology Center for their

technical support, especially the Flow Cytometry Facility, MIT BioMicro Center, and Biopolymers and Proteomics Core. We also thank the Division of Comparative Medicine at MIT. We would like to thank Mark Karver and the Peptide Synthesis Core Facility at Northwestern University for production of amphiphile vaccine reagents. This facility is currently supported by the Soft and Hybrid Nanotechnology Experimental (SHyNE) Resource (NSF ECCS-2025633) and has also been supported by the Simpson Querrey Institute for BioNanotechnology, Northwestern University Office for Research, U.S. Army Research Office, and the U.S. Army Medical Research and Materiel Command.

References

1. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. *Nature* (2014) 515:568–571. doi:10.1038/nature13954
2. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. *Science* (2015) 348:69–74. doi:10.1126/science.aaa4971
3. Heemskerk B, Kvistborg P, Schumacher TNM. The cancer antigenome. *EMBO J* (2013) 32:194–203. doi:10.1038/emboj.2012.333
4. Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. *Nat Rev Cancer* (2014) 14:135–146. doi:10.1038/nrc3670
5. Sharma P, Allison JP. The future of immune checkpoint therapy. *Science* (2015) 348:56–61. doi:10.1126/science.aaa8172
6. Curran MA, Glisson BS. New Hope for therapeutic cancer vaccines in the era of immune checkpoint modulation. *Annu Rev Med* (2019) 70:409–424. doi:10.1146/annurev-med-050217-121900
7. Gascoigne NRJ, Rybakina V, Acuto O, Brzostek J. TCR signal strength and T cell development. *Annu Rev Cell Dev Biol* (2016) 32:327–348. doi:10.1146/annurev-cellbio-111315-125324
8. Slansky JE, Rattis FM, Boyd LF, Fahmy T, Jaffee EM, Schneck JP, Margulies DH, Pardoll DM. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. *Immunity* (2000) 13:529–538. doi:10.1016/s1074-7613(00)00052-2
9. McMahan RH, McWilliams JA, Jordan KR, Dow SW, Wilson DB, Slansky JE. Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. *J Clin Invest* (2006) 116:2543–2551. doi:10.1172/JCI26936
10. Birnbaum ME, Mendoza JL, Sethi DK, Dong S, Glanville J, Dobbins J, Ozkan E, Davis MM, Wucherpfennig KW, Garcia KC. Deconstructing the peptide-MHC specificity of T cell recognition. *Cell* (2014) 157:1073–1087. doi:10.1016/j.cell.2014.03.047

Identification of cross-reactive mimotopes

- 715 11. Sewell AK. Why must T cells be cross-reactive? *Nat Rev Immunol* (2012) 12:669–677.
716 doi:10.1038/nri3279
- 717 12. Wooldridge L, Ekeruche-Makinde J, van den Berg HA, Skowera A, Miles JJ, Tan MP, Dolton G,
718 Clement M, Llewellyn-Lacey S, Price DA, et al. A single autoimmune T cell receptor recognizes
719 more than a million different peptides. *J Biol Chem* (2012) 287:1168–1177.
720 doi:10.1074/jbc.M111.289488
- 721 13. Jordan KR, McMahan RH, Kemmler CB, Kappler JW, Slansky JE. Peptide vaccines prevent tumor
722 growth by activating T cells that respond to native tumor antigens. *Proc Natl Acad Sci U S A*
723 (2010) 107:4652–4657. doi:10.1073/pnas.0914879107
- 724 14. Jordan KR, Buhrman JD, Sprague J, Moore BL, Gao D, Kappler JW, Slansky JE. TCR hypervariable
725 regions expressed by T cells that respond to effective tumor vaccines. *Cancer Immunol*
726 *Immunother* (2012) 61:1627–1638. doi:10.1007/s00262-012-1217-5
- 727 15. de Visser KE, Cordaro TA, Kessels HW, Tirion FH, Schumacher TN, Kruisbeek AM. Low-avidity
728 self-specific T cells display a pronounced expansion defect that can be overcome by altered
729 peptide ligands. *J Immunol* (2001) 167:3818–3828. doi:10.4049/jimmunol.167.7.3818
- 730 16. Moynihan KD, Opel CF, Szeto GL, Tzeng A, Zhu EF, Engreitz JM, Williams RT, Rakhra K, Zhang
731 MH, Rothschilds AM, et al. Eradication of large established tumors in mice by combination
732 immunotherapy that engages innate and adaptive immune responses. *Nat Med* (2016)
733 22:1402–1410. doi:10.1038/nm.4200
- 734 17. Kline J, Zhang L, Battaglia L, Cohen KS, Gajewski TF. Cellular and molecular requirements for
735 rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic
736 proliferation. *J Immunol* (2012) 188:2630–2642. doi:10.4049/jimmunol.1100845
- 737 18. Kang BH, Momin N, Moynihan KD, Silva M, Li Y, Irvine DJ, Wittrup KD. Immunotherapy-induced
738 antibodies to endogenous retroviral envelope glycoprotein confer tumor protection in mice.
739 *PLoS One* (2021) 16:e0248903. doi:10.1371/journal.pone.0248903
- 740 19. Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM,
741 Snyder A, et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA
742 including endogenous retroviruses. *Cell* (2015) 162:974–986. doi:10.1016/j.cell.2015.07.011
- 743 20. Yang JC, Perry-Lalley D. The envelope protein of an endogenous murine retrovirus is a tumor-
744 associated T-cell antigen for multiple murine tumors. *J Immunother* (2000) 23:177–183.
745 doi:10.1097/00002371-200003000-00001
- 746 21. Rossjohn J, Gras S, Miles JJ, Turner SJ, Godfrey DI, McCluskey J. T cell antigen receptor
747 recognition of antigen-presenting molecules. *Annu Rev Immunol* (2015) 33:169–200.
748 doi:10.1146/annurev-immunol-032414-112334
- 749 22. Liu H, Moynihan KD, Zheng Y, Szeto GL, Li AV, Huang B, Van Egeren DS, Park C, Irvine DJ.
750 Structure-based programming of lymph-node targeting in molecular vaccines. *Nature* (2014)
751 507:519–522. doi:10.1038/nature12978

Identification of cross-reactive mimotopes

- 752 23. Mehta NK, Pradhan RV, Soleimany AP, Moynihan KD, Rothschilds AM, Momin N, Rakhra K,
753 Mata-Fink J, Bhatia SN, Wittrup KD, et al. Pharmacokinetic tuning of protein-antigen fusions
754 enhances the immunogenicity of T-cell vaccines. *Nat Biomed Eng* (2020) 4:636–648.
755 doi:10.1038/s41551-020-0563-4
- 756 24. Moynihan KD, Holden RL, Mehta NK, Wang C, Karver MR, Dinter J, Liang S, Abraham W, Melo
757 MB, Zhang AQ, et al. Enhancement of peptide vaccine immunogenicity by increasing lymphatic
758 drainage and boosting serum stability. *Cancer Immunol Res* (2018) 6:1025–1038.
759 doi:10.1158/2326-6066.CIR-17-0607
- 760 25. Liu GY, Fairchild PJ, Smith RM, Prowle JR, Kioussis D, Wraith DC. Low avidity recognition of self-
761 antigen by T cells permits escape from central tolerance. *Immunity* (1995) 3:407–415.
762 doi:10.1016/1074-7613(95)90170-1
- 763 26. Morgan DJ, Kreuwel HT, Fleck S, Levitsky HI, Pardoll DM, Sherman LA. Activation of low avidity
764 CTL specific for a self epitope results in tumor rejection but not autoimmunity. *J Immunol*
765 (1998) 160:643–651. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/9551898>
- 766 27. de Visser KE, Cordaro TA, Kioussis D, Haanen JB, Schumacher TN, Kruisbeek AM. Tracing and
767 characterization of the low-avidity self-specific T cell repertoire. *Eur J Immunol* (2000) 30:1458–
768 1468. doi:10.1002/(SICI)1521-4141(200005)30:5<1458::AID-IMMU1458>3.0.CO;2-2
- 769 28. Nugent CT, Morgan DJ, Biggs JA, Ko A, Pilip IM, Pamer EG, Sherman LA. Characterization of
770 CD8+ T lymphocytes that persist after peripheral tolerance to a self antigen expressed in the
771 pancreas. *J Immunol* (2000) 164:191–200. doi:10.4049/jimmunol.164.1.191
- 772 29. Theobald M, Biggs J, Hernández J, Lustgarten J, Labadie C, Sherman LA. Tolerance to p53 by
773 A2.1-restricted cytotoxic T lymphocytes. *J Exp Med* (1997) 185:833–841.
774 doi:10.1084/jem.185.5.833
- 775 30. Colella TA, Bullock TN, Russell LB, Mullins DW, Overwijk WW, Luckey CJ, Pierce RA, Restifo NP,
776 Engelhard VH. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma
777 antigen: implications for tumor immunotherapy. *J Exp Med* (2000) 191:1221–1232.
778 doi:10.1084/jem.191.7.1221
- 779 31. Fremont DH, Stura EA, Matsumura M, Peterson PA, Wilson IA. Crystal structure of an H-2Kb-
780 ovalbumin peptide complex reveals the interplay of primary and secondary anchor positions in
781 the major histocompatibility complex binding groove. *Proc Natl Acad Sci U S A* (1995) 92:2479–
782 2483. doi:10.1073/pnas.92.7.2479
- 783 32. Degano M, Garcia KC, Apostolopoulos V, Rudolph MG, Teyton L, Wilson IA. A functional hot
784 spot for antigen recognition in a superagonist TCR/MHC complex. *Immunity* (2000) 12:251–
785 261. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/10755612>
- 786 33. Shitaoka K, Hamana H, Kishi H, Hayakawa Y, Kobayashi E, Sukegawa K, Piao X, Lyu F, Nagata T,
787 Sugiyama D, et al. Identification of tumoricidal TCRs from tumor-infiltrating lymphocytes by
788 single-cell analysis. *Cancer Immunol Res* (2018) 6:378–388. doi:10.1158/2326-6066.CIR-17-
789 0489

- 790 34. Aoki H, Ueha S, Shichino S, Ogiwara H, Hashimoto S-I, Kakimi K, Ito S, Matsushima K. TCR
791 repertoire analysis reveals mobilization of novel CD8+ T cell clones into the Cancer-Immunity
792 Cycle following anti-CD4 antibody administration. *Front Immunol* (2018) 9:3185.
793 doi:10.3389/fimmu.2018.03185
- 794 35. Lefranc M-P, Giudicelli V, Duroux P, Jabado-Michaloud J, Folch G, Aouinti S, Carillon E,
795 Duvergey H, Houles A, Paysan-Lafosse T, et al. IMGT®, the international ImMunoGeneTics
796 information system® 25 years on. *Nucleic Acids Res* (2015) 43:D413-22.
797 doi:10.1093/nar/gku1056
- 798 36. Madi A, Shifrut E, Reich-Zeliger S, Gal H, Best K, Ndifon W, Chain B, Cohen IR, Friedman N. T-
799 cell receptor repertoires share a restricted set of public and abundant CDR3 sequences that are
800 associated with self-related immunity. *Genome Res* (2014) 24:1603–1612.
801 doi:10.1101/gr.170753.113
- 802 37. Venturi V, Kedzierska K, Price DA, Doherty PC, Douek DC, Turner SJ, Davenport MP. Sharing of T
803 cell receptors in antigen-specific responses is driven by convergent recombination. *Proc Natl
804 Acad Sci U S A* (2006) 103:18691–18696. doi:10.1073/pnas.0608907103
- 805 38. Li H, Ye C, Ji G, Han J. Determinants of public T cell responses. *Cell Res* (2012) 22:33–42.
806 doi:10.1038/cr.2012.1
- 807 39. Quigley MF, Greenaway HY, Venturi V, Lindsay R, Quinn KM, Seder RA, Douek DC, Davenport
808 MP, Price DA. Convergent recombination shapes the clonotypic landscape of the naive T-cell
809 repertoire. *Proc Natl Acad Sci U S A* (2010) 107:19414–19419. doi:10.1073/pnas.1010586107
- 810 40. Stoye JP. Studies of endogenous retroviruses reveal a continuing evolutionary saga. *Nat Rev
811 Microbiol* (2012) 10:395–406. doi:10.1038/nrmicro2783
- 812 41. Mouse Genome Sequencing Consortium, Waterston RH, Lindblad-Toh K, Birney E, Rogers J,
813 Abril JF, Agarwal P, Agarwala R, Ainscough R, Alexandersson M, et al. Initial sequencing and
814 comparative analysis of the mouse genome. *Nature* (2002) 420:520–562.
815 doi:10.1038/nature01262
- 816 42. Stocking C, Kozak CA. Murine endogenous retroviruses. *Cell Mol Life Sci* (2008) 65:3383–3398.
817 doi:10.1007/s00018-008-8497-0
- 818 43. Jenkins NA, Copeland NG, Taylor BA, Lee BK. Organization, distribution, and stability of
819 endogenous ecotropic murine leukemia virus DNA sequences in chromosomes of *Mus
820 musculus*. *J Virol* (1982) 43:26–36. doi:10.1128/JVI.43.1.26-36.1982
- 821 44. Pothlichet J, Mangeney M, Heidmann T. Mobility and integration sites of a murine C57BL/6
822 melanoma endogenous retrovirus involved in tumor progression in vivo. *Int J Cancer* (2006)
823 119:1869–1877. doi:10.1002/ijc.22066
- 824 45. King SR, Berson BJ, Risser R. Mechanism of interaction between endogenous ecotropic murine
825 leukemia viruses in (BALB/c X C57BL/6) hybrid cells. *Virology* (1988) 162:1–11.
826 doi:10.1016/0042-6822(88)90388-1

- 827 46. Dewannieux M, Heidmann T. Endogenous retroviruses: acquisition, amplification and taming of
828 genome invaders. *Curr Opin Virol* (2013) 3:646–656. doi:10.1016/j.coviro.2013.08.005
- 829 47. Rowe HM, Trono D. Dynamic control of endogenous retroviruses during development. *Virology*
830 (2011) 411:273–287. doi:10.1016/j.virol.2010.12.007
- 831 48. Maksakova IA, Mager DL, Reiss D. Keeping active endogenous retroviral-like elements in check:
832 the epigenetic perspective. *Cell Mol Life Sci* (2008) 65:3329–3347. doi:10.1007/s00018-008-
833 8494-3
- 834 49. Geis FK, Goff SP. Silencing and transcriptional regulation of endogenous retroviruses: An
835 overview. *Viruses* (2020) 12:884. doi:10.3390/v12080884
- 836 50. Kassiotis G. Endogenous retroviruses and the development of cancer. *J Immunol* (2014)
837 192:1343–1349. doi:10.4049/jimmunol.1302972
- 838 51. Ruprecht K, Mayer J, Sauter M, Roemer K, Mueller-Lantzsch N. Endogenous retroviruses and
839 cancer. *Cell Mol Life Sci* (2008) 65:3366–3382. doi:10.1007/s00018-008-8496-1
- 840 52. Hayashi H, Matsubara H, Yokota T, Kuwabara I, Kanno M, Koseki H, Isono K, Asano T, Taniguchi
841 M. Molecular cloning and characterization of the gene encoding mouse melanoma antigen by
842 cDNA library transfection. *J Immunol* (1992) 149:1223–1229. Available at:
843 <https://www.ncbi.nlm.nih.gov/pubmed/1380036>
- 844 53. Li M, Muller J, Xu F, Hearing VJ, Gorelik E. Inhibition of melanoma-associated antigen
845 expression and ecotropic retrovirus production in B16BL6 melanoma cells transfected with
846 major histocompatibility complex class I genes. *Cancer Res* (1996) 56:4464–4474. Available at:
847 <https://www.ncbi.nlm.nih.gov/pubmed/8813142>
- 848 54. Li M, Xu F, Muller J, Hearing VJ, Gorelik E. Ecotropic C-type retrovirus of B16 melanoma and
849 malignant transformation of normal melanocytes. *Int J Cancer* (1998) 76:430–436.
850 doi:10.1002/(sici)1097-0215(19980504)76:3<430::aid-ijc23>3.0.co;2-d
- 851 55. Li M, Huang X, Zhu Z, Gorelik E. Sequence and insertion sites of murine melanoma-associated
852 retrovirus. *J Virol* (1999) 73:9178–9186. doi:10.1128/JVI.73.11.9178-9186.1999
- 853 56. Zeh HJ 3rd, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High avidity CTLs for two self-
854 antigens demonstrate superior in vitro and in vivo antitumor efficacy. *J Immunol* (1999)
855 162:989–994. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/9916724>
- 856 57. Kershaw MH, Hsu C, Mondesire W, Parker LL, Wang G, Overwijk WW, Lapointe R, Yang JC,
857 Wang RF, Restifo NP, et al. Immunization against endogenous retroviral tumor-associated
858 antigens. *Cancer Res* (2001) 61:7920–7924. Available at:
859 <https://www.ncbi.nlm.nih.gov/pubmed/11691813>
- 860 58. Bronte V, Cingarlini S, Apolloni E, Serafini P, Marigo I, De Santo C, Macino B, Marin O, Zanovello
861 P. Effective genetic vaccination with a widely shared endogenous retroviral tumor antigen

- 862 requires CD40 stimulation during tumor rejection phase. *J Immunol* (2003) 171:6396–6405.
863 doi:10.4049/jimmunol.171.12.6396
- 864 59. Kudo-Saito C, Schlom J, Hodge JW. Induction of an antigen cascade by diversified
865 subcutaneous/intratumoral vaccination is associated with antitumor responses. *Clin Cancer Res*
866 (2005) 11:2416–2426. doi:10.1158/1078-0432.CCR-04-1380
- 867 60. Fernandez-Poma SM, Salas-Benito D, Lozano T, Casares N, Riezu-Boj J-I, Mancheño U, Elizalde
868 E, Alignani D, Zubeldia N, Otano I, et al. Expansion of tumor-infiltrating CD8+ T cells expressing
869 PD-1 improves the efficacy of adoptive T-cell therapy. *Cancer Res* (2017) 77:3672–3684.
870 doi:10.1158/0008-5472.CAN-17-0236
- 871 61. Ye X, Waite JC, Dhanik A, Gupta N, Zhong M, Adler C, Malahias E, Ni M, Wei Y, Gurer C, et al.
872 Endogenous retroviral proteins provide an immunodominant but not requisite antigen in a
873 murine immunotherapy tumor model. *Oncoimmunology* (2020) 9:1758602.
874 doi:10.1080/2162402X.2020.1758602
- 875 62. McWilliams JA, Sullivan RT, Jordan KR, McMahan RH, Kemmler CB, McDuffie M, Slansky JE.
876 Age-dependent tolerance to an endogenous tumor-associated antigen. *Vaccine* (2008)
877 26:1863–1873. doi:10.1016/j.vaccine.2008.01.052
- 878 63. Kemmler CB, Clambey ET, Kedl RM, Slansky JE. Elevated tumor-associated antigen expression
879 suppresses variant peptide vaccine responses. *J Immunol* (2011) 187:4431–4439.
880 doi:10.4049/jimmunol.1101555
- 881 64. Odaka T. Genetic transmission of endogenous N- and B-tropic murine leukemia viruses in low-
882 leukemic strain C57BL/6. *J Virol* (1975) 15:332–337. doi:10.1128/JVI.15.2.332-337.1975
- 883 65. Young GR, Ploquin MJ-Y, Eksmond U, Wadwa M, Stoye JP, Kassiotis G. Negative selection by an
884 endogenous retrovirus promotes a higher-avidity CD4+ T cell response to retroviral infection.
885 *PLoS Pathog* (2012) 8:e1002709. doi:10.1371/journal.ppat.1002709
- 886 66. Chan KF, Gully BS, Gras S, Beringer DX, Kjer-Nielsen L, Cebon J, McCluskey J, Chen W, Rossjohn
887 J. Divergent T-cell receptor recognition modes of a HLA-I restricted extended tumour-
888 associated peptide. *Nat Commun* (2018) 9:1–13. doi:10.1038/s41467-018-03321-w
- 889 67. Adams JJ, Narayanan S, Liu B, Birnbaum ME, Kruse AC, Bowerman NA, Chen W, Levin AM,
890 Connolly JM, Zhu C, et al. T cell receptor signaling is limited by docking geometry to peptide-
891 major histocompatibility complex. *Immunity* (2011) 35:681–693.
892 doi:10.1016/j.immuni.2011.09.013
- 893 68. Sibener LV, Fernandes RA, Kolawole EM, Carbone CB, Liu F, McAfee D, Birnbaum ME, Yang X,
894 Su LF, Yu W, et al. Isolation of a Structural Mechanism for Uncoupling T Cell Receptor Signaling
895 from Peptide-MHC Binding. *Cell* (2018) 174:672-687.e27. doi:10.1016/j.cell.2018.06.017
- 896 69. Huang AY, Gulden PH, Woods AS, Thomas MC, Tong CD, Wang W, Engelhard VH, Pasternack G,
897 Cotter R, Hunt D, et al. The immunodominant major histocompatibility complex class I-

- 898 restricted antigen of a murine colon tumor derives from an endogenous retroviral gene
899 product. *Proc Natl Acad Sci U S A* (1996) 93:9730–9735. doi:10.1073/pnas.93.18.9730
- 900 70. Pedersen AE, Buus S, Claesson MH. Treatment of transplanted CT26 tumour with dendritic cell
901 vaccine in combination with blockade of vascular endothelial growth factor receptor 2 and
902 CTLA-4. *Cancer Lett* (2006) 235:229–238. doi:10.1016/j.canlet.2005.04.012
- 903 71. Stringhini M, Spadafora I, Catalano M, Mock J, Probst P, Spörri R, Neri D. Cancer therapy in
904 mice using a pure population of CD8+ T cell specific to the AH1 tumor rejection antigen. *Cancer*
905 *Immunol Immunother* (2021) 70:3183–3197. doi:10.1007/s00262-021-02912-9
- 906 72. Buhrman JD, Slansky JE. Improving T cell responses to modified peptides in tumor vaccines.
907 *Immunol Res* (2013) 55:34–47. doi:10.1007/s12026-012-8348-9
- 908 73. Buhrman JD, Jordan KR, Munson DJ, Moore BL, Kappler JW, Slansky JE. Improving antigenic
909 peptide vaccines for cancer immunotherapy using a dominant tumor-specific T cell receptor. *J*
910 *Biol Chem* (2013) 288:33213–33225. doi:10.1074/jbc.M113.509554
- 911 74. Buhrman JD, Jordan KR, U'ren L, Sprague J, Kemmler CB, Slansky JE. Augmenting antitumor T-
912 cell responses to mimotope vaccination by boosting with native tumor antigens. *Cancer Res*
913 (2013) 73:74–85. doi:10.1158/0008-5472.CAN-12-1005
- 914 75. Wang L, Amoozgar Z, Huang J, Saleh MH, Xing D, Orsulic S, Goldberg MS. Decitabine enhances
915 lymphocyte migration and function and synergizes with CTLA-4 blockade in a Murine ovarian
916 cancer model. *Cancer Immunol Res* (2015) 3:1030–1041. doi:10.1158/2326-6066.CIR-15-0073
- 917 76. Ghoneim HE, Fan Y, Moustaki A, Abdelsamed HA, Dash P, Dogra P, Carter R, Awad W, Neale G,
918 Thomas PG, et al. De Novo epigenetic programs inhibit PD-1 blockade-mediated T cell
919 rejuvenation. *Cell* (2017) 170:142–157.e19. doi:10.1016/j.cell.2017.06.007
- 920 77. Jansz N, Faulkner GJ. Endogenous retroviruses in the origins and treatment of cancer. *Genome*
921 *Biol* (2021) 22:147. doi:10.1186/s13059-021-02357-4
- 922 78. Petrizzo A, Ragone C, Cavalluzzo B, Mauriello A, Manolio C, Tagliamonte M, Buonaguro L.
923 Human endogenous retrovirus reactivation: Implications for cancer immunotherapy. *Cancers*
924 *(Basel)* (2021) 13:1999. doi:10.3390/cancers13091999
- 925 79. Xue B, Sechi LA, Kelvin DJ. Human endogenous retrovirus K (HML-2) in health and disease.
926 *Front Microbiol* (2020) 11:1690. doi:10.3389/fmicb.2020.01690
- 927 80. Kassiotis G, Stoye JP. Making a virtue of necessity: the pleiotropic role of human endogenous
928 retroviruses in cancer. *Philos Trans R Soc Lond B Biol Sci* (2017) 372:
929 doi:10.1098/rstb.2016.0277
- 930 81. Young GR, Stoye JP, Kassiotis G. Are human endogenous retroviruses pathogenic? An approach
931 to testing the hypothesis. *Bioessays* (2013) 35:794–803. doi:10.1002/bies.201300049

Identification of cross-reactive mimotopes

82. Smith CC, Beckermann KE, Bortone DS, De Cubas AA, Bixby LM, Lee SJ, Panda A, Ganesan S, Bhanot G, Wallen EM, et al. Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. *J Clin Invest* (2018) 128:4804–4820. doi:10.1172/JCI121476
83. Panda A, de Cubas AA, Stein M, Riedlinger G, Kra J, Mayer T, Smith CC, Vincent BG, Serody JS, Beckermann KE, et al. Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. *JCI Insight* (2018) 3: doi:10.1172/jci.insight.121522
84. Solovyov A, Vabret N, Arora KS, Snyder A, Funt SA, Bajorin DF, Rosenberg JE, Bhardwaj N, Ting DT, Greenbaum BD. Global cancer transcriptome quantifies repeat element polarization between immunotherapy responsive and T cell suppressive classes. *Cell Rep* (2018) 23:512–521. doi:10.1016/j.celrep.2018.03.042
85. Büscher K, Trefzer U, Hofmann M, Sterry W, Kurth R, Denner J. Expression of human endogenous retrovirus K in melanomas and melanoma cell lines. *Cancer Res* (2005) 65:4172–4180. doi:10.1158/0008-5472.CAN-04-2983
86. Muster T, Waltenberger A, Grassauer A, Hirschl S, Caucig P, Romirer I, Födinger D, Seppel H, Schanab O, Magin-Lachmann C, et al. An endogenous retrovirus derived from human melanoma cells. *Cancer Res* (2003) 63:8735–8741. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/14695188>
87. Humer J, Waltenberger A, Grassauer A, Kurz M, Valencak J, Rapberger R, Hahn S, Löwer R, Wolff K, Bergmann M, et al. Identification of a melanoma marker derived from melanoma-associated endogenous retroviruses. *Cancer Res* (2006) 66:1658–1663. doi:10.1158/0008-5472.CAN-05-2452
88. Schiavetti F, Thonnard J, Colau D, Boon T, Coulie PG. A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes. *Cancer Res* (2002) 62:5510–5516. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/12359761>
89. Zhou F, Krishnamurthy J, Wei Y, Li M, Hunt K, Johanning GL, Cooper LJ, Wang-Johanning F. Chimeric antigen receptor T cells targeting HERV-K inhibit breast cancer and its metastasis through downregulation of Ras. *Oncoimmunology* (2015) 4:e1047582. doi:10.1080/2162402X.2015.1047582
90. Krishnamurthy J, Rabinovich BA, Mi T, Switzer KC, Olivares S, Maiti SN, Plummer JB, Singh H, Kumaresan PR, Huls HM, et al. Genetic engineering of T cells to target HERV-K, an ancient retrovirus on melanoma. *Clin Cancer Res* (2015) 21:3241–3251. doi:10.1158/1078-0432.CCR-14-3197
91. HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma. Available at: <https://clinicaltrials.gov/ct2/show/NCT03354390> [Accessed February 6, 2022]
92. Sacha JB, Kim I-J, Chen L, Ullah JH, Goodwin DA, Simmons HA, Schenkman DI, von Pelchrzim F, Gifford RJ, Nimityongskul FA, et al. Vaccination with cancer- and HIV infection-associated

- 970 endogenous retrotransposable elements is safe and immunogenic. *J Immunol* (2012)
971 189:1467–1479. doi:10.4049/jimmunol.1200079
- 972 93. Han A, Glanville J, Hansmann L, Davis MM. Linking T-cell receptor sequence to functional
973 phenotype at the single-cell level. *Nat Biotechnol* (2014) 32:684–692. doi:10.1038/nbt.2938
- 974 94. Dash P, McClaren JL, Oguin TH, Rothwell W, Todd B, Morris MY, Becksfort J, Reynolds C, Brown
975 SA, Doherty PC, et al. Paired analysis of TCR α and TCR β chains at the single-cell level in mice. *J*
976 *Clin Invest* (2011) 121:288–295. doi:10.1172/JCI44752
- 977 95. Magoč T, Salzberg SL. FLASH: fast length adjustment of short reads to improve genome
978 assemblies. *Bioinformatics* (2011) 27:2957–2963. doi:10.1093/bioinformatics/btr507
- 979 96. Shugay M, Britanova OV, Merzlyak EM, Turchaninova MA, Mamedov IZ, Tuganbaev TR, Bolotin
980 DA, Staroverov DB, Putintseva EV, Plevova K, et al. Towards error-free profiling of immune
981 repertoires. *Nat Methods* (2014) 11:653–655. doi:10.1038/nmeth.2960
- 982 97. Li S, Lefranc M-P, Miles JJ, Alamyar E, Giudicelli V, Duroux P, Freeman JD, Corbin VDA,
983 Scheerlinck J-P, Frohman MA, et al. IMGT/HighV QUEST paradigm for T cell receptor IMGT
984 clonotype diversity and next generation repertoire immunoprofiling. *Nat Commun* (2013)
985 4:2333. doi:10.1038/ncomms3333
- 986 98. Wang C, Cui A, Bukenya M, Aung A, Pradhan D, Whittaker CA, Agarwal Y, Thomas A, Liang S,
987 Amlashi P, et al. Reprogramming NK cells and macrophages via combined antibody and
988 cytokine therapy primes tumors for elimination by checkpoint blockade. *Cell Rep* (2021)
989 37:110021. doi:10.1016/j.celrep.2021.110021
- 990 99. Gierahn TM, Wadsworth MH, Hughes TK, Bryson BD, Butler A, Satija R, Fortune S, Love JC,
991 Shalek AK. Seq-Well: portable, low-cost RNA sequencing of single cells at high throughput. *Nat*
992 *Methods* (2017) 14:395–398. doi:10.1038/nmeth.4179
- 993 100. Hughes TK, Wadsworth MH 2nd, Gierahn TM, Do T, Weiss D, Andrade PR, Ma F, de Andrade
994 Silva BJ, Shao S, Tsoi LC, et al. Second-Strand Synthesis-based massively parallel scRNA-seq
995 reveals cellular states and molecular features of human inflammatory skin pathologies.
996 *Immunity* (2020) 53:878-894.e7. doi:10.1016/j.immuni.2020.09.015
- 997 101. Macosko EZ, Basu A, Satija R, Nemesh J, Shekhar K, Goldman M, Tirosh I, Bialas AR, Kamitaki N,
998 Martersteck EM, et al. Highly Parallel Genome-wide Expression Profiling of Individual Cells
999 Using Nanoliter Droplets. *Cell* (2015) 161:1202–1214. doi:10.1016/j.cell.2015.05.002
- 1000 102. Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data
1001 across different conditions, technologies, and species. *Nat Biotechnol* (2018) 36:411–420.
1002 doi:10.1038/nbt.4096
- 1003 103. Tu AA, Gierahn TM, Monian B, Morgan DM, Mehta NK, Ruiter B, Shreffler WG, Shalek AK, Love
1004 JC. TCR sequencing paired with massively parallel 3' RNA-seq reveals clonotypic T cell
1005 signatures. *Nat Immunol* (2019) 20:1692–1699. doi:10.1038/s41590-019-0544-5

1006 104. Ottina E, Levy P, Eksmond U, Merckenschlager J, Young GR, Roels J, Stoye JP, Tüting T, Calado
1007 DP, Kassiotis G. Restoration of endogenous retrovirus infectivity impacts mouse cancer models.
1008 *Cancer Immunol Res* (2018) 6:1292–1300. doi:10.1158/2326-6066.CIR-18-0038

1009 105. Schmittgen TD, Zakrajsek BA. Effect of experimental treatment on housekeeping gene
1010 expression: validation by real-time, quantitative RT-PCR. *J Biochem Biophys Methods* (2000)
1011 46:69–81. doi:10.1016/s0165-022x(00)00129-9

1012 106. Ramachandiran V, Grigoriev V, Lan L, Ravkov E, Mertens SA, Altman JD. A robust method for
1013 production of MHC tetramers with small molecule fluorophores. *J Immunol Methods* (2007)
1014 319:13–20. doi:10.1016/j.jim.2006.08.014

1015 107. Lybarger L, Yu YYL, Miley MJ, Fremont DH, Myers N, Primeau T, Truscott SM, Connolly JM,
1016 Hansen TH. Enhanced immune presentation of a single-chain major histocompatibility complex
1017 class I molecule engineered to optimize linkage of a C-terminally extended peptide. *J Biol Chem*
1018 (2003) 278:27105–27111. doi:10.1074/jbc.M303716200

1019 108. Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries.
1020 *Nat Biotechnol* (1997) 15:553–557. doi:10.1038/nbt0697-553

1021 109. Chao G, Lau WL, Hackel BJ, Sazinsky SL, Lippow SM, Wittrup KD. Isolating and engineering
1022 human antibodies using yeast surface display. *Nat Protoc* (2006) 1:755–768.
1023 doi:10.1038/nprot.2006.94

1024 110. Masella AP, Bartram AK, Truszkowski JM, Brown DG, Neufeld JD. PANDAseq: paired-end
1025 assembler for illumina sequences. *BMC Bioinformatics* (2012) 13:31. doi:10.1186/1471-2105-
1026 13-31

1027 111. Fu L, Niu B, Zhu Z, Wu S, Li W. CD-HIT: accelerated for clustering the next-generation
1028 sequencing data. *Bioinformatics* (2012) 28:3150–3152. doi:10.1093/bioinformatics/bts565

1029

Tables

Table 1: CDR3 sequences and gene usage for T cells with strikingly similar TCR sequences. The clone size and mouse in which the clone was identified are also shown.

Clone Name	Clone Size	Mouse	CDR3 α	TRAV	TRAJ	CDR3 β	TRBV	TRBD	TRBJ
7PPG1	26	AIP 2	CAAKDYSNNRLTL	7-2	7	CASS PPG DTQYF	3	1	2-5
7PPG2	22	AIP 1	CAAKDYSNNRLTL	10	7	CASS PPG GSEVFF	5	1	1-1
7PPG3	12	AIP 3	CAAKDYSNNRLTL	10	7	CASS PPG SQNTLYF	5	1	2-4
7ELG1	9	AIP 2	CAASDYSNNRLTL	7-2	7	CASS L ELG GREQYF	16	2	2-7
7PPG4	6	AIP 3	CAAKDYSNNRLTL	10D	7	CASS PPG QNTTEVFF	4	1	1-1
7DLG1	3	untr	CAAKDYSNNRLTL	10D	7	CASS QDL GNSDYTF	5	1	1-2
7DLG2	3	AIP 2	CAAKDYSNNRLTL	10D	7	CASS QDL GYAEQFF	5	2	2-1
7AQG1	2	untr	CAASDYSNNRLTL	7-2	7	CASS QAQ GGGAEQFF	5	1	2-1
7EGA1	2	AIP 2	CAAKDYSNNRLTL	5D-4	7	CASS QEG ANTEVFF	2	1	1-1
7PPG5	1	untr	CAAKDYSNNRLTL	10	7	CASS PPG VNTEVFF	5	1	1-1
7DPG1	1	AIP 1	CAAKDYSNNRLTL	10	7	CASS QDP GGNAEQFF	2	2	2-1
7PPG6	1	AIP 3	CAAKDYSNNRLTL	10	7	CASS PPG GDTEVFF	5	1	1-1
7TPG1	1	AIP 2	CAAKDYSNNRLTL	7-2	7	CAS STPG QNTTEVFF	4	1	1-1
7NWS1	1	AIP 2	CAASDYSNNRLTL	7-2	7	CASS L NWS QDTQYF	16	2	2-5

Figures

Figure 1: The T cell response following combination immunotherapy of melanoma is oligoclonal and contains a set of homologous T cell clones. (A) Timeline of tumor inoculation, therapy, and cell sorting (n=5 mice/group, s.c. = subcutaneous). (B) Clonality of T cell responses in individual treated mice and pooled untreated mice. T cells with identical alpha and beta chain sequences were identified as members of a clone. N indicates the number of T cells for which paired TCR sequences were obtained. Orange colored clones appear in Table 1.

Identification of cross-reactive mimotopes

A

B

C

Figure 2: TCR-transduced T cells are activated by an endogenous retrovirus peptide expressed by multiple tumor types. (A-B) 58^{-/-} cells transduced to express the 7PPG2, 7PPG4, and 2C TCRs were cocultured with B16F10, B16.SIY, MC-38, and TC-1 cancer cell lines at various effector:target ratios (A) or with DC2.4 cells loaded with p15E or SIY peptide (B). T cell activation was assessed by IL-2 ELISA. Data shown are mean+s.e.m. of triplicate (A) or duplicate (B) samples and are representative of 3 independent experiments. (C) Surface plasmon resonance was performed to quantify affinities between four TCRs and KSPWFTTL peptide presented by H-2K^b.

Identification of cross-reactive mimotopes

Figure 3: Sequencing of T cells from AIP-treated melanomas reveals significant expansion in the p15E-tetramer⁺ fraction.

(A) Clone sizes in tetramer-positive and tetramer-negative populations from TILs isolated from AIP-treated mice as revealed by single-cell T cell sequencing. (B) Unsupervised gene expression analysis of CD8⁺ TILs reveals five distinct transcriptomic clusters. (C) Distribution of tetramer-positive and tetramer-negative cells amongst the 5 clusters. (D) Clusters 1 and 5 show enrichment for expanded clonal TCR sequences. (E) Clone sizes of isolated TILs mapped onto the clusters as determined in B. (F) Expression of a selection of T cell effector and phenotype genes for each transcriptomic cluster. Scaled expression of common genes is indicated by color, and the fraction of cells in that cluster expressing the gene is indicated by relative dot size.

Identification of cross-reactive mimotopes

Figure 4: Vaccination against p15E induces minimal expansion of p15E-reactive T cells and does not result in tumor protection. (A) Timeline of vaccination and tumor inoculation. (B) On days 21 and 35, peripheral blood samples from each mouse were stimulated with p15E peptide in the presence of brefeldin A for 4 hours. Intracellular cytokine staining was performed to assess CD8⁺ T cell reactivity to p15E peptide. *P<0.05 by one-way ANOVA with Tukey's multiple comparisons test. Data shown is mean±s.e.m. (C-D) Tumor areas were measured every other day beginning 3 days post-inoculation. Mice were euthanized when tumor area exceeded 100 mm². Shown are tumor areas for individual mice (C) and survival (D). N=5 mice/group.

Identification of cross-reactive mimotopes

Figure 5: Screening of a yeast displayed peptide-MHC library allowed the identification of mimotopes that more potently activate T cells of interest.

(A) Deep sequencing was performed on yeast following each round of selection to reveal amino acid preferences for binding to 7PPG2 and 7PPG4 TCRs. Heat maps show preference for each peptide position, weighted by read count, following 3 rounds of selection with the indicated TCR. (B) TCR-transduced T cells were cocultured with DC2.4 cells loaded with mimotope or p15E peptides. T cell activation was assessed by IL-2 ELISA. Data shown are mean+s.e.m. for triplicate samples and are representative of 3 independent experiments. (C) Surface plasmon resonance was used to quantify affinities between TCRs and mimotope or p15E peptides displayed by H-2K^b.

Identification of cross-reactive mimotopes

Figure 6: Peptide-pulsed target cells are specifically killed *in vivo* following vaccination with mimotopes.

(A) Timeline of vaccination, donor splenocyte injection, and analysis. (B) Schematic of day 35-36 protocol for *in vivo* killing assay. (C) On day 36, spleens were removed from experimental mice. Single cell suspensions were generated and analyzed by flow cytometry for the presence of CFSE- and violet-dyed cells. ns=not significant: $P>0.05$, *** $P<0.001$, **** $P<0.0001$ by one-way ANOVA with Tukey's multiple comparisons test. Data shown are mean±s.e.m and are representative of 2 independent experiments. N=3 mice/group.

Identification of cross-reactive mimotopes

Figure 7: Vaccination against mimotopes promotes the expansion of CD8⁺ T cells reactive to p15E and can result in tumor growth delay. (A) Timeline of vaccination and tumor inoculation. (B-C) On days 21 and 35, peripheral blood samples from each mouse were stimulated with p15E peptide in the presence of brefeldin A for 4 hours. Intracellular cytokine staining was performed to assess the fraction of CD8⁺ T cells within live cells (B) and CD8⁺ T cell reactivity to p15E peptide (C). **P<0.01, ***P<0.001, ****P<0.0001 by one-way ANOVA with Tukey's multiple comparisons test. Data shown are mean+s.e.m. (D-E) Tumor areas were measured every other day beginning 3 days post-inoculation. Mice were euthanized when tumor area exceeded 100 mm². Shown are tumor areas for individual mice (D) and survival (E). *P<0.05 by log-rank (Mantel-Cox) test. N=5 mice/group.